News Search Results
Jan 16, 2026, 13:43 ET AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
0.96 [95% CI 0.77 to 1.20]). EPCORE DLBCL-1 is the first Phase 3 study to demonstrate improvement in PFS in patients with R/R DLBCL who were treated with a CD3xCD20 T-cell engaging bispecific monotherapy. The global study enrolled 483 patients with R/R DLBCL with at least one prior line of therapy
More news about: AbbVie
Jan 15, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)." Although the press release described the data in positive terms, the press release reported that adverse events occurred in two patients, one of
More news about: Pomerantz LLP
Jan 12, 2026, 07:00 ET Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
patients with heavily pre-treated multiple myeloma; and (iii) under accelerated approval in adult patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. XPOVIO® (also known as NEXPOVIO® in certain countries) has
More news about: Karyopharm Therapeutics Inc.
Jan 08, 2026, 16:05 ET ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
Executive Officer of ADC Therapeutics. "This year, we look forward to multiple clinical catalysts including full results from our LOTIS-5 and LOTIS-7 2L+ DLBCL trials, as well as potentially from the ongoing Phase 2 indolent lymphoma IITs. Assuming positive results, we anticipate potential compendia inclusion
More news about: ADC Therapeutics SA
Jan 08, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)." Although the press release described the data in positive terms, the press release reported that adverse events occurred in two patients, one of
More news about: Pomerantz LLP
Jan 02, 2026, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.
Jan 01, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)." Although the press release described the data in positive terms, the press release reported that adverse events occurred in two patients, one of
More news about: Pomerantz LLP
Dec 19, 2025, 07:55 ET Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
levels."We're excited that these data continue to demonstrate a manageable safety profile and strong efficacy including deep and durable responses in 2L+ r/r DLBCL patients treated with ZYNLONTA plus glofitamab," said Mohamed Zaki, MD, PhD, CMO of ADC Therapeutics. "We are well on the way to completing enrollment
More news about: Equity Insider
Dec 16, 2025, 20:00 ET Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma
Application (sNDA) for XPOVIO® (selinexor) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least 2 lines of systemic therapy, who are ineligible for autologous stem cell transplant.
More news about: Antengene Corporation Limited
Dec 11, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)." Although the press release described the data in positive terms, the press release reported that adverse events occurred in two patients, one of which
More news about: Pomerantz LLP
Dec 10, 2025, 08:00 ET Bantam Pharmaceutical Announces First Patient Treated in BTM-3566 Phase 1 Clinical Trial at Princess Margaret Cancer Centre in Toronto
anti-cancer activity, showing complete regressions in patient-derived xenograft (PDX) models of aggressive B-cell lymphomas, including double- and triple-hit DLBCL and in MCL PDX models from patient tumors that progressed on rituximab, BTK inhibitors and CAR-T therapies. BTM-3566 exhibits activity in solid tumors,
More news about: Bantam Pharmaceutical, LLC
Dec 08, 2025, 07:00 ET Karyopharm to Participate in Baird's Biotech Discovery Series
indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.
Dec 03, 2025, 07:30 ET ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated
More news about: ADC Therapeutics SA
Dec 02, 2025, 16:05 ET ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
More news about: ADC Therapeutics SA
Dec 02, 2025, 08:15 ET AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
certain types of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma that has come back (relapsed) or that did not respond (refractory), after 2 or more treatments.EPKINLY for the treatment of DLBCL is approved based on patient response data. Studies are
More news about: AbbVie Inc.
Dec 02, 2025, 08:00 ET Rutgers Cancer Institute and RWJBarnabas Health to Showcase Practice-Changing Blood Cancer Research at the 67th American Society of Hematology Annual Meeting and Exposition
first report from Part 1 of the Phase 3 OLYMPIA-3 study examined odronextamab plus chemotherapy in previously untreated diffuse large B-cell lymphoma (DLBCL). The Part 1A analysis assessed two dose levels in 22 patients, with primary endpoints focused on dose-limiting toxicities and treatment-emergent adverse
More news about: Rutgers Cancer Institute and RWJBarnabas Health
Dec 01, 2025, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.
Dec 01, 2025, 07:00 ET Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference
indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.
Nov 21, 2025, 12:39 ET Hackensack Meridian John Theurer Cancer Center Unveils Research at the 67th American Society of Hematology Annual Meeting
25-13458)LymphomaEpcoritamab + R-mini-CHOP results in 2-year remissions and high MRD negativity rates in elderly patients with newly diagnosed DLBCL: Results from the EPCORE NHL-2 trial (ABSTRACT 25-3828) Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance
More news about: Hackensack Meridian John Theurer Cancer Center
Nov 18, 2025, 12:47 ET AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
certain types of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma that has come back (relapsed) or that did not respond (refractory), after 2 or more treatments.EPKINLY for the treatment of DLBCL is approved based on patient response data. Studies are ongoing
More news about: AbbVie
Nov 10, 2025, 07:30 ET ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
2L+ DLBCL once the pre-specified number of progression-free survival (PFS) events is reached and data are available. Assuming positive results, a supplemental Biologics License Application (sBLA) submission to regulatory authorities will follow, with potential confirmatory approval in 2L+ DLBCL as well
More news about: ADC Therapeutics SA
Nov 03, 2025, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.
Nov 03, 2025, 09:15 ET CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B
6e8) and 6 DLBCL patients (cell dose 3e8: 1 patient; 4.5e8: 1 patient; 6e8: 4 patients). The details are below: Six patients were evaluable for efficacy, achieving an ORR of 83.3%, comprising 4 patients who achieved CR (2 MCL, 2 DLBCL) and 1 patient
More news about: CARsgen Therapeutics
Nov 03, 2025, 07:00 ET Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
patients with heavily pre-treated multiple myeloma; and (iii) under accelerated approval in adult patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. XPOVIO® (also known as NEXPOVIO® in certain countries) has
More news about: Karyopharm Therapeutics Inc.
Oct 31, 2025, 07:49 ET AbbVie Reports Third-Quarter 2025 Financial Results
patients in the outpatient setting for the first full dose of Epkinly (epcoritamab) monotherapy in adult patients with R/R diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of systemic therapy. Results from the study demonstrated that the incidence and severity of cytokine release
More news about: AbbVie